Traditional and emerging molecular markers in neuroblastoma prognosis: The good, the bad and the ugly

Abstract.

Background: Neuroblastomas (NB) are a heterogeneous group of childhood tumours with a wide range of likelihood for tumour progression. As traditional parameters do not ensure completely accurate prognostic grouping, new molecular markers are needed for assessing the individual patient's prognosis more precisely. Patients and Methods: 133 NB of all stages were analysed in blind-trial fashion for telomerase activity (TA), expression of survivin, and MYCN status. These data were correlated with other traditional prognostic indicators and disease outcome. Results and Conclusions: TA is a powerful independent prognostic marker for all stages and is capable of differentiating between good and poor outcome in putative “favourable” clinical or biological subgroups of NB patients. High survivin expression is associated with an adverse outcome, but is more difficult to interprete than TA because survivin expression needs to be accurately quantified to be of predictive value. We propose an extended progression model for NB including emerging prognostic markers, with emphasis on telomerase activity.

Hintergrund: Neuroblastome (NB) sind eine heterogene Gruppe kindlicher Tumoren mit einer großen Variabilität der Wahrscheinlichkeit der Tumorprogression. Da traditionelle Parameter keine vollständig genauen prognostischen Vorhersagen erlauben, sind neue molekulare Marker zur Prognoseeinschätzung erforderlich. Patienten und Methoden: 133 NB aller Stadien wurden im Blindversuch auf Telomeraseaktivität (TA), Survivin-Expression und den N-MYC-Status untersucht. Diese Daten wurden mit anderen traditionellen prognostischen Parametern und dem Krankheitsverlauf korreliert. Ergebnisse und Schlussfolgerung: Telomeraseaktivität ist ein sehr aussagekräftiger, unabhängiger prognostischer Marker für alle Stadien und vermag auch in den vermeintlich günstigen klinischen oder biologischen Untergruppen der NB zwischen einem günstigen bzw. ungünstigen Krankheitsverlauf zu unterscheiden. Eine hohe Survivin-Expression ist auch mit einem ungünstigen Krankheitsverlauf korreliert, ist aber schwieriger zu interpretieren als TA, da ein prädiktiver Wert nur durch genaue Quantifizierung erreicht wird. Wir propagieren eine erweitertes Progressionsmodell des Neuroblastoms unter Einbeziehung neuer prognostischer Marker mit Betonung der Telomeraseaktivität.

Neuroblastoma - telomerase - survivin - progression model

Neuroblastom - Telomerase - Survivin - Progressionsmodell

Literatur

• 01 Maris  J M, Matthay  K K. Molecular biology of neuroblastoma.  J Clin Oncol. 1999;  17(7) 2264-2279
• 02 Ambros  P F, Ambros  I M, Strehl  S, Bauer  S, Luegmayr  A, Kovar  H et al. Regression and progression in neuroblastoma. Does genetics predict tumour behaviour?.  Eur J Cancer. 1995;  31A(4) 510-515
• 03 Shimada  H, Ambros  I M, Dehner  L P, Hata  J, Joshi  V V, Roald  B et al. The International Neuroblastoma Pathology Classification (the Shimada system).  Cancer. 1999;  86(2) 364-372
• 04 Shimada  H, Ambros  I M, Dehner  L P, Hata  J, Joshi  V V, Roald  B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.  Cancer. 1999;  86(2) 349-363
• 05 Tanaka  T, Matsumura  T, Iehara  T, Sawada  T. Risk of unfavorable character among neuroblastomas detected through mass screening.  Med Pediatr Oncol. 2000;  35(6) 705-707
• 06 Gallego  S, Parareda  A, Munell  F, Sanchez  dT, Reventos  J. Clinical relevance of molecular markers in neuroblastoma: results from a single institution.  Oncol Rep. 1999;  6(4) 891-896
• 07 Brodeur  G M, Ambros  P F FM. Biological aspects of neuroblastoma screening.  Med Pediatr Oncol. 1998;  31 394-400
• 08 Eggert  A, Ikegaki  N, Liu  X G, Brodeur  G M. Prognostic and biological role of neurotrophin-receptor TrkA and TrkB in neuroblastoma.  Klin Pädiatr. 2000;  212(4) 200-205
• 09 Bown  N, Cotterill  S, Lastowska  M, O'Neill  S, Pearson  A DJ, Plantaz  et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.  N Engl J Med. 1999;  340(25) 1954-1961
• 10 Kawa  K, Ohnuma  N, Kaneko  M, Yamamoto  K, Etoh  T, Mugishima  H et al. Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months.  J Clin Oncol. 1999;  17(10) 3216-3220
• 11 Brinkschmidt  C, Poremba  C, Christiansen  H, Simon  R, Schäfer  K-L, Terpe  H J et al. Comparative genomic hybridization and telomerase activity analysis identify two biologically different groups of 4s neuroblastomas.  Br J Cancer. 1998;  77(12) 2223-2229
• 12 Poremba  C, Willenbring  H, Hero  B, Christiansen  H, Schäfer  K-L, Brinkschmidt  C et al. Telomerase activity distinguishes between neuroblastomas with good and poor prognosis.  Ann Oncol. 1999;  10(6) 715-721
• 13 Poremba  C, Hero  B, Heine  B, Scheel  C, Schäfer  K-L, Christiansen  H et al. Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas.  Med Pediatr Oncol. 2000;  35(6) 651-655
• 14 Poremba  C, Scheel  C, Hero  B, Christiansen  H, Schäfer  K-L, Nakayama  J et al. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues.  J Clin Oncol. 2000;  18(13) 2582-2592
• 15 Choi  L M, Kim  N W, Zuo  J J, Gerbing  R, Stram  D, Lukens  J N et al. Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma.  Med Pediatr Oncol. 2000;  35(6) 647-650
• 16 Islam  A, Kageyama  H, Takada  N, Kawamoto  T, Takayasu  H, Isogai  E et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma.  Oncogene. 2000;  19(5) 617-623
• 17 Poremba  C, Shroyer  K R, Frost  M, Diallo  R, Fogt  F, Schäfer  K-L et al. Telomerase is a highly sensitive and specific molecular marker in fine-needle aspirates of breast lesions.  J Clin Oncol. 1999;  17 2020-2026
• 18 Poremba  C, Böcker  W, Willenbring  H, Schäfer  K-L, Otterbach  F, Bürger  H et al. Telomerase activity in human proliferative breast lesions.  Int J Oncol. 1998;  12 641-648
• 19 Fogt  F, Poremba  C, Shibao  K, Itoh  H, Kohno  K, Zimmerman  R L et al. Expression of survivin, YB-1 and Ki-67 in sporadic adenomas and DALM lesions in ulcerative colitis.  Applied Immunohistochemistry and Molecular Morphology. 2001;  9 143-149
• 20 Katzenstein  H M, Bowman  L C, Brodeur  G M, Thorner  P S, Joshi  V V, Smith  E I et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience - a pediatric oncology group study.  J Clin Oncol. 1998;  16(6) 2007-2017
• 21 Spengler  B A, Lazarova  D L, Ross  R A, Biedler  J L. Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells.  Oncol Res. 1997;  9(9) 467-476
• 22 Nakagawara  A, Nakamura  Y, Ikeda  H, Hiwasa  T, Kuida  K, Su  M S et al. High levels of expression and nuclear localization of interleukin-1 beta converting enzyme (ICE) and CPP32 in favorable human neuroblastomas.  Cancer Res. 1997;  57(20) 4578-4584
• 23 Koizumi  H, Ohkawa  I, Tsukahara  T, Momoi  T, Nakada  K, Uchikoshi  T. Apoptosis in favourable neuroblastomas is not dependent on Fas (CD95/APO-1) expression but on activated caspase 3 (CPP32).  J Pathol. 1999;  189(3) 410-415
• 24 Adida  C, Berrebi  D, Peuchmaur  M, Reyes-Mugica  M, Altieri  D C. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma [letter].  Lancet. 1998;  351(9106) 882-883
• 25 Islam  A, Kageyama  H, Hashizume  K, Kaneko  Y, Nakagawara  A. Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin- beta/2B.  Med Pediatr Oncol. 2000;  35(6) 550-553